Paracetamolo S.A.L.F.

Paracetamol, the active ingredient in Paracetamolo S.A.L.F., is an analgesic presented as an intravenous solution for injection use. It reduces pain and fever in adult patients when administered under medical supervision.

GNH USA supplies Paracetamolo S.A.L.F. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory documentation for cross‑border distribution. Clients benefit from reliable logistics, temperature‑controlled shipping where required, and responsive technical support throughout the procurement process, ensuring product integrity from manufacture to bedside.

Paracetamol acts centrally to relieve pain and lower fever by modulating prostaglandin synthesis.

- Pain: provides analgesia for mild to moderate acute pain. - Fever: reduces elevated body temperature in febrile states. - Post‑operative pain: helps control discomfort after surgical procedures.

Paracetamol administered intravenously may be associated with several adverse reactions.

Common Side Effects: - Injection site pain: mild discomfort at the infusion site. - Nausea: transient feeling of queasiness. - Transient hypotension: brief drop in blood pressure during rapid infusion. - Headache: mild to moderate head discomfort. - Elevated liver enzymes: mild, reversible increase. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Stevens‑Johnson syndrome: rare severe skin reaction. - Hepatotoxicity: significant liver injury, especially with overdose. - Blood dyscrasias: rare blood cell abnormalities. - Renal impairment: acute kidney injury in susceptible patients. - Severe hypotension: prolonged low blood pressure needing intervention.

When using Paracetamolo S.A.L.F., clinicians should consider several safety measures.

- Dose adjustment: modify dose in patients with hepatic impairment. - Monitoring: regularly assess liver function tests during prolonged therapy. - Allergy assessment: verify no known hypersensitivity to paracetamol or excipients. - Concomitant drugs: avoid use with other hepatotoxic agents when possible. - Pediatric use: restrict to approved age groups and weight‑based dosing. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Paracetamol can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, monitor INR closely. - Carbamazepine: may reduce paracetamol clearance, risk of toxicity.

Moderate Interactions (Monitor Closely): - Alcohol: additive hepatotoxic risk, advise limited consumption. - Isoniazid: potential for enhanced liver enzyme elevation. - Rifampicin: may increase metabolism, reducing analgesic effect. - Phenobarbital: may lower plasma concentrations, monitor response.